Mission Statement, Vision, & Core Values (2026) of China National Medicines Corporation Ltd.

As a listed arm of Sinopharm under the ticker 600511.SS, China National Medicines Corporation Ltd. has grown from serving Beijing to a nationwide pharmaceutical powerhouse offering more than 13,000 drug types sourced from over 2,200 suppliers, supplying specialty portfolios-anesthetics, psychiatric agents, high-end prescriptions, essential medicines and blood products-through direct selling, distribution, e‑commerce and bonded warehousing to over 2,000 corporate customers across 31 provinces; anchored by a mission to operationalize the national strategy for Traditional Chinese Medicine with targeted R&D investment, a vision to build a sustainable, synergistic TCM industry chain and core values of integrity, dedication, perseverance and the pursuit of excellence, CNMC's scale, channel depth and strategic focus set the stage for a closer look at how these elements translate into competitive advantage and sector leadership.

China National Medicines Corporation Ltd. (600511.SS) - Intro

• Listed ticker: 600511.SS
• Parent: China National Pharmaceutical Group Corporation (Sinopharm)
• Primary markets: Nationwide coverage across 31 provinces and regions
• Product reach: Over 13,000 types of drugs sourced from more than 2,200 suppliers

• Business lines: direct selling, pharmaceutical distribution, warehouse logistics, e-commerce, bonded warehousing, and pharmaceutical manufacturing
• Specialty focuses: anesthetics, psychiatric drugs, high‑end prescription medicines, essential medicines, and blood products
• Customer network: serves 2,000+ corporate customers including hospitals, specialty clinics, and institutional buyers
• Supply chain assets: national distribution network enabling presence in all 31 provinces

• Mission: Integrate distinctive healthcare resources to ensure high‑quality access to specialty pharmaceuticals and medical supplies across China.
• Vision: To lead the specialty pharmaceutical distribution sector in China by building an efficient, compliant, and innovation‑driven supply chain capable of serving complex clinical needs.
• Core values:
  • Patient-centered service and clinical safety
  • Regulatory compliance and quality assurance
  • Operational excellence in logistics and warehousing
  • Collaborative supplier partnerships and innovation
  • Integrity, transparency, and social responsibility

• Strengthen specialty portfolio: increase proportion of high‑end prescription and specialty drugs within overall sales mix year‑on‑year.
• Expand digital & bonded services: scale e‑commerce and bonded warehousing to shorten supply lead times and improve cross‑border procurement efficiency.
• Optimize logistics: enhance cold‑chain and high‑value drug distribution capabilities to reduce spoilage and ensure compliance.
• Deepen customer penetration: grow the institutional customer base beyond 2,000 accounts and extend service depth per hospital/clinic.

China National Medicines Corporation Ltd. (600511.SS) - Overview

• Mission focus: advance TCM integration within national healthcare policy and expand access to traditional therapies across urban and rural China.
• Strategic orientation: center investments on R&D, manufacturing scale-up, and regulatory compliance to support high-quality TCM products.
• Stakeholder alignment: coordinate with provincial TCM initiatives, state-owned pharmacopeia standards, and public health campaigns.

• R&D and modernization: targeted clinical trials and formulation upgrades to enhance efficacy, safety, and GMP compliance-supported by the ≈RMB 1.3 billion annual R&D budget.
• Manufacturing & quality: investment in GMP-certified production lines and supply-chain traceability to meet national pharmacopeia standards and export requirements.
• Market access & distribution: expanding provincial distribution hubs and hospital formulary inclusion to improve TCM accessibility across public health networks.
• Strategic partnerships: collaborations with research institutes, TCM hospitals, and provincial health authorities to scale pilot programs and evidence-generation.

• Vision: position China National Medicines Corporation Ltd. as a national champion for evidence-based, high-quality TCM that complements modern medicine and supports China's Healthy China strategy.
• Five-year targets (strategic aims): revenue growth ahead of TCM market CAGR, increasing R&D intensity to 3-4% of revenue, and expanding export footprints in targeted Asian and Belt-and-Road markets.
• KPIs monitored: hospital formulary inclusion counts, GMP-certified production capacity (units/year), number of clinical studies registered, and revenue contribution from new products.

• Revenue resilience tied to China's aging population and continued policymaker support for TCM integration into primary care.
• R&D and quality investments imply near-term margin pressure but aim to enhance long-term market differentiation and pricing power.
• Export and Belt-and-Road opportunities present upside if regulatory harmonization and international clinical acceptance progress.

China National Medicines Corporation Ltd. (600511.SS) - Mission Statement

• Integrate upstream raw-material cultivation, standardized processing, and GMP production to secure medicine quality and traceability.
• Scale downstream distribution, hospital supply, and community healthcare to improve patient access to TCM therapies nationwide.
• Invest in R&D, clinical validation, and modern formulation technologies to strengthen evidence-based TCM products.
• Foster strategic alliances with regional producers, research institutes, and healthcare providers to build an integrated industrial ecosystem.

• Industry ecosystem: Develop multi-party collaboration across cultivation bases, processing centres, manufacturing plants, distribution networks, and clinical partners.
• Scale & sustainability: Drive scale economies while implementing sustainable sourcing and green manufacturing practices.
• Evidence & innovation: Pair traditional formulations with modern R&D, aiming for broader clinical acceptance and regulatory alignment.
• Market leadership: Target top-tier market positioning in key TCM segments through selective M&A, investment, and capability development.

• Standardized sourcing: Scale proprietary cultivation bases with traceability systems and quality controls to reduce raw-material variability.
• GMP & quality assurance: Expand certified manufacturing lines and real-time analytics to maintain regulatory compliance across markets.
• Clinical integration: Sponsor multi-center studies and hospital partnerships to validate efficacy, improve formularies, and accelerate adoption.
• Digital supply chain: Deploy ERP/WMS and blockchain traceability to shorten lead times and improve inventory turns.

• Vertical integration to capture margin across cultivation→manufacture→distribution.
• Portfolio optimization: prioritize high-growth therapeutic categories and export-ready formulations.
• Platform partnerships: co-develop regional hubs and engage in selective strategic M&A to consolidate fragmented suppliers.
• ESG alignment: adopt green manufacturing, worker safety programs, and community cultivation projects to secure long-term licences to operate.

China National Medicines Corporation Ltd. (600511.SS) - Vision Statement

• Integrity: Commitment to transparency, regulatory compliance, and ethical conduct in all operations.
• Dedication: Focused investment in R&D, manufacturing quality, and service capability to meet healthcare needs.
• Perseverance: Resilience in navigating policy shifts, market cycles, and supply-chain challenges.
• Pursuit of Excellence: Continuous improvement in product quality, operational efficiency, and corporate governance.

• Integrity - governance structures, third-party audits, whistleblower channels, and public disclosure cadence to minimize compliance incidents.
• Dedication - capital allocation targets toward manufacturing upgrades and R&D spending tied to product lifecycle goals.
• Perseverance - contingency inventories, multi-sourcing strategies, and scenario planning to maintain supply amid disruptions.
• Pursuit of Excellence - continuous improvement programs, supplier scorecards, and employee training metrics to raise quality standards.